960 research outputs found
The volume activated potassium channel KCNK5 is up-regulated in activated human T Cells, but volume regulation is impaired
Background/Aims: The potential role of the two-pore domain potassium channel KCNK5 (also known as TASK-2 and K2P5.1) in activated T cell physiology has only recently been described. So far KCNK5 has been described to be up-regulated in T cells in multiple sclerosis patients and to be implicated in the volume regulatory mechanism regulatory volume decrease (RVD) in T cells. Methods: We investigated the time-dependent expression pattern of KCNK5 in CD3/CD28 activated human T cells using qPCR and Western blotting and its role in RVD using a Coulter Counter. Results: KCNK5 is highly up-regulated in CD3/CD28 activated T cells both at mRNA (after 24 h) and protein level (72 and 144 h), but despite this up-regulation the RVD response is inhibited. Furthermore, the swelling-activated Cl- permeability in activated T cells is strongly decreased, and the RVD inhibition is predominantly due to the decreased Cl- permeability. Conclusion: The up-regulated KCNK5 in activated human T cells does not play a volume regulatory role, due to decreased Cl- permeability. We speculate that the KCNK5 up-regulation might play a role in hyperpolarization of the cell membrane leading to increased Ca2+ influx and proliferation of T cells
Increased incidence of gonorrhoea and chlamydia in Greenland 1990-2012
Background: Since the 1970s, Greenland has presented the highest reported incidence rates of the sexually transmitted infections (STIs) gonorrhoea and chlamydia in the Arctic regions. Objective: This study aims to describe sex- and age-specific incidence rates of gonorrhoea and chlamydia from 1990 to 2012 in Greenland, and to evaluate if changes in case definitions, diagnostic procedures and implementation of STI interventions during the period coincide with rate changes. Design: Gonorrhoea and chlamydia cases were identified from the national STI surveillance. For 1990–2008, STI cases were identified from weekly notified aggregated data. For 2009–2012, cases were identified in person-identifiable national registers. We used log-linear Poisson regression to calculate incidence rates (IRs) and incidence rate ratios (IRRs) with 95% confidence intervals (95% CI). Analyses were stratified according to sex, age and calendar period. Results: Gonorrhoea and chlamydia incidence rates have increased since 1995 to reach 2,555 per 100,000 person-years (PY) for gonorrhoea and 6,403 per 100,000 PY for chlamydia in 2012. From 2006 to 2012, the incidence rates among young adults aged 15–19 years were 8,187 and 22,515 per 100,000 PY for gonorrhoea and chlamydia, respectively. Changes in surveillance reporting did not seem to influence the incidence rates for either disease, whereas a change in diagnostic test coincided with an increased incidence of chlamydia. Conclusion: Overall, the incidence of chlamydia in Greenland increased during the study period, whereas the incidence of gonorrhoea decreased until 1995 but increased thereafter. Young adults aged 15–24 years were at highest risk of infection. The increase in incidence rates was independent of changes in case definitions, whereas an observed increase in chlamydia incidence in 2005 coincided with a change in diagnostic test. None of the STI interventions launched after 1995 seemed to coincide with decreasing national incidence rates
Dynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma
The introduction of immune checkpoint inhibition for recurrent and metastatic head and
neck cancer has brought a new treatment option for patients suffering from advanced oral cancers
without a chance for curation using surgery or radiotherapy. The application of immune checkpoint
inhibitors in most cases is based on the expression levels of PD-L1 in the tumor tissue. To date, there
is a lack of data on the dynamic regulation of PD-L1 during disease progression. Therefore, this study
aimed to evaluate the expression levels of PD-L1 in a large cohort of patients (n = 222) with oral
squamous cell carcinoma including primary and recurrent tumors. Semiautomatic digital pathology
scoring was used for the assessment of PD-L1 expression levels in primary and recurrent oral
squamous cell carcinoma. Survival analysis was performed to evaluate the prognostic significance
of the protein expression at different stages of the disease. We found a significant up-regulation
of PD-L1 expression from primary disease to recurrent tumors (mean PD-L1 H-scores: primary
tumors: 47.1 ± 31.4; recurrent tumors: 103.5 ± 62.8, p < 0.001). In several cases, a shift from low
PD-L1 expression in primary tumors to high PD-L1 expression in recurrent tumors was identified.
Multivariate Cox regression analysis did not reveal a significantly higher risk of death (p = 0.078)
or recurrence (p = 0.926) in patients with higher PD-L1 expression. Our findings indicate that the
exclusive analysis of primary tumor tissue prior to the application of checkpoint blockade may lead
to the misjudgment of PD-L1 expression in recurrent tumors
Long-Term Exposure to Traffic-Related Air Pollution Associated with Blood Pressure and Self-Reported Hypertension in a Danish Cohort
Background: Short-term exposure to air pollution has been associated with changes in blood pressure (BP) and emergency department visits for hypertension, but little is known about the effects of long-term exposure to traffic-related air pollution on BP and hypertension
Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes.
The pneumococcus is a leading global pathogen and a key virulence factor possessed by the majority of pneumococci is an antigenic polysaccharide capsule ('serotype'), which is encoded by the capsular (cps) locus. Approximately 100 different serotypes are known, but the extent of sequence diversity within the cps loci of individual serotypes is not well understood. Investigating serotype-specific sequence variation is crucial to the design of sequence-based serotyping methodology, understanding pneumococcal conjugate vaccine (PCV) effectiveness and the design of future PCVs. The availability of large genome datasets makes it possible to assess population-level variation among pneumococcal serotypes and in this study 5405 pneumococcal genomes were used to investigate cps locus diversity among 49 different serotypes. Pneumococci had been recovered between 1916 and 2014 from people of all ages living in 51 countries. Serotypes were deduced bioinformatically, cps locus sequences were extracted and variation was assessed within the cps locus, in the context of pneumococcal genetic lineages. Overall, cps locus sequence diversity varied markedly: low to moderate diversity was revealed among serogroups/types 1, 3, 7, 9, 11 and 22; whereas serogroups/types 6, 19, 23, 14, 15, 18, 33 and 35 displayed high diversity. Putative novel and/or hybrid cps loci were identified among all serogroups/types apart from 1, 3 and 9. This study demonstrated that cps locus sequence diversity varied widely between serogroups/types. Investigation of the biochemical structure of the polysaccharide capsule of major variants, particularly PCV-related serotypes and those that appear to be novel or hybrids, is warranted.This work was supported by a Wellcome Trust Biomedical Research
Fund award (04992/Z/14/Z) to M. J. C. M., K. A. J., and A. B. B.; a
Wellcome Trust career development fellowship (083511/Z/07/Z) to
A. B. B; and a University of Oxford John Fell Fund award (123/734)
to A. B. B. Core funding for the Sanger Institute was provided by the
Wellcome Trust (098051). Funding for the Icelandic vaccine impact
study was provided by GlaxoSmithKline Biologicals SA and the Landspítali University Hospital Research Fund to K. G. K., A. H., H. E., S.
D. B., and A. B. B
- …